Literature DB >> 2767713

Expression of natural killer (NK) cell-specific alloantigens on a mouse NK-like cell line.

Y C Smart1, K L Stevenson, R F Thorne, W D Thomas, L H Hsu, R C Burton.   

Abstract

As part of the strategy for screening for natural killer (NK) cell-specific monoclonal antibodies (MoAb) we have raised a number of murine NK-like cell lines in media containing interleukin-2 (IL-2). The detection of specific NK cell alloantigens on a C57BL/6 cell line in long-term culture in IL-2 is the subject of this paper. The C57BL/6 cell line has the morphology of large granular lymphocytes (LGL) and exhibits strong cytolytic activity against the archetype NK cell target, YAC-1. Absorption of three anti-NK antiserum, NZB anti-BALB/c (anti-NK-2.1), BALB/c anti-DBA/2 (anti-NK-3.1) and CE anti-CBA (anti-NK-4.1), with the C57BL/6 cell line removed the anti-NK activity from these antisera. Flow cytometric studies of the C57BL/6 cell line demonstrated significant binding of the anti-NK-1.1 MoAb produced by hybridoma PK136. Our results suggest that the C57BL/6 NK-like cell line exhibits some of the properties of naive NK cells and expresses all the known NK cell-specific alloantigens, NK-1.1, NK-2.1, NK-3.1 and NK-4.1 and therefore is potentially useful in selecting NK specific hybridomas and in studying the biology of NK cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2767713     DOI: 10.1038/icb.1989.36

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  2 in total

1.  Monoclonal antibody anti-NC-2 identifies a second receptor on cells mediating natural cytotoxicity in mice.

Authors:  H Shirzadeh; R C Burton; J H Brien; Y C Smart
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

2.  Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation.

Authors:  Courtney M Lappas; Yuan-Ji Day; Melissa A Marshall; Victor H Engelhard; Joel Linden
Journal:  J Exp Med       Date:  2006-11-06       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.